Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.


Updates from The Motley Fool

Latest updates on Neurocrine Biosciences from Fool.com.
3 Biotech Stocks to Buy in July

Looking for hot biotech stocks to buy in July? Here are three Motley Fool healthcare contributors...

3 Stocks to Get on Your Watchlist

A big-box retail giant, an up-and-coming developer of a tardive dyskinesia treatment, and a short...

This Week in Biotech

The buddy system works well for three companies this week while three others take a dive followin...



Stock Performance

View Interactive NBIX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Neurocrine Biosciences.
Current Price: $42.72
Prev Close: $43.08
Open: $42.78
Bid: $37.50
Ask: $46.60
Day's Range: $41.89 - $43.14
52wk Range: $32.18 - $55.15
Volume: 651,609
Avg Vol 1,117,365
Market Cap: $4B
P/E (ttm): -26.43
EPS (ttm): ($1.63)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Neurocrine Biosciences.
CAPS Rating 4 out of 5
 
317 Outperform
45 Underperform
CAPS All Stars
 
85 Outperform
6 Underperform

How do you think Neurocrine Biosciences will perform against the market?



You pick for Neurocrine Biosciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Kevin C. Gorman, CEO

81% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Neurocrine Biosciences.

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers